Citations

Clear

3042 citation(s) found for "Kumar, S".

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma
Nedved, Adrienne, Chen, Lu , Roua, Arian, Abidoye, Seyi, Choi, Yun Young , Pongas, Georgios , Zhuang, Tony , Clement, Jean, Sears-Smith, Megan , Sun, Laura , Willis, H., Munoz, Javier, Lossos, Izidore S., Wang, Michael , Cohen, Jonathon B. , Martin, Peter , Beaven, Anne , Joseph, Ashlee , Shafagati, Nazila , Rosenlind, Kira, Hill, Brian T. , Wagner‐Johnston, Nina, Kumar, Anita , Lunning, Matthew A. , Pak, Stacy, Danilov, Alexey V. , Lopedote, Paolo , Watkins, Marcus P. , Moustafa, Muhamad Alhaj , Clement, Jean, Willis, Hannah, Kahl, Brad S. , Bond, David A. , Munoz, Javier, Lossos, Izidore S. , Portell, Craig A. , Ghosh, Nilanjan , Abramson, Jeremy S. , Reagan, Patrick Michael , Ermann, Daniel A. , Brooks, Taylor , McLoughlin, Daniel E. , Farooq, Umar , Karmali, Reem , Shree, Tanaya , Wang, Yucai , Phillips, Tycel

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5351-5351

10.1182/blood-2025-5351 Get It

Abstract Introduction: cBTKi have made a substantial impact in pts w/ MCL, but pts who develop PD while on treatment w/ cBTKi have historically had poor responses to subsequent lines of therapy (LOT). Brexucel, lisocel, and the non-covalent BTKi pirto have been approved in this population. While two RW studies have substantiated the benefit of brexucel, similar data for pirto are lacking. Accordingly, we aimed to evaluate the outcomes of pts treated w/ pirto in the RW setting. Methods: We performed a multi-center retrospective cohort study of adult pts w/ a diagnosis of MCL who experienced PD after any approved cBTKi and subsequently received pirto. Pts who received pirto w/ bridging intent and those who switched to pirto due to intolerance of cBTKi were excluded. The 95% exact binomial confidence intervals (CI) were calculated for overall response rate (ORR) and complete response rate (CRR). Progression-free survival (PFS) and overall survival (OS) were defined as the time from pirto start to PD or death, whichever occurred first, and the time from pirto start to death, respectively, and calculated w/ the Kaplan-Meier method. The log-rank test was used to compare survival curves. A multivariate (MV) Cox proportional hazard model was built to calculate adjusted hazard ratio (aHR). Analyses were performed w/ SAS, version 9.4. Results: Data on 111 pts w/ MCL treated across 21 institutions were collected. Median (mdn) age was 72 (range 33 – 93) years. Twenty-seven pts (24%) were female, 3 (3%) were Asian, 5 (5%) Black, 9 (8%) Hispanic, 86 (77%) White. Among the 53 (48%) pts w/ available MIPI-c at diagnosis, 28 (53%) pts were high-risk. Ki67 at diagnosis was available in 84 (76%) pts: of those, 58 (69%) had a Ki67 ≥30%, and 41 (49%) ≥50%. TP53 mutational status was available in 70 (63%) pts: 33 (47%) had documented TP53 mutation and 10/52 (19%) pts had a disease w/ complex karyotype. Pts had a mdn of 3 (range 1 – 9) prior LOT (n=106). Ninety-one pts (86%) received chemo-immunotherapy (CIT), 16 (15%) autologous stem cell transplant, 19 (18%) venetoclax (ven), 29 (27%) chimeric antigen receptor T-cell, 4 (4%) allogeneic stem cell transplant. For cBTKi, 39 (35%) pts received ibrutinib, 56 (50%) pts acalabrutinib, 33 (30%) pts zanubrutinib, and 17 (15%) pts received more than one cBTKi. The mdn time from the last dose of cBTKi to pirto start was 55 (range 0 – 2587) days, w/ 51 (46%) pts who switched from a cBTKi directly to pirto. Thirty (27%) pts had no response (stable disease or PD as best response) to cBTKi, and 40 (36%) pts had no response to the last LOT. Two (2%) pts received pirto in combination w/ CIT, 8 (7%) w/ an anti-CD20 monoclonal antibody (mAb), 11 (10%) w/ ven ± a mAb, while 86 (77%) pts as single agent. In 104 (94%) pts, pirto was given at full dose, 10 (9%) pts had a subsequent dose reduction. A total of 35 serious (grade ≥3) adverse events (AE) were documented in 27 (24%) pts: 4 (4%) pts had a serious bleeding AE, 5 (5%) pts a serious cardiac AE, 10 (9%) a serious GI AE, and 16 (14%) a serious infectious AE. Ninety-eight (88%) pts were evaluable for response. The ORR was 40% (95% CI 30% – 50%) w/ a CRR of 29% (95% CI 20%– 39%). At the last follow-up, 29 (26%) pts remained on pirto w/ a mdn treatment duration of 15.1 months (range 0.4 – 26). Fifty-eight (52%) pts died, 35 (78%) because of PD. At a mdn follow-up of 15.8 (range 0.4 – 26) months among survivors, the mdn PFS was 4.7 months (95% CI 3.3 – 8.2) and the mdn OS was 13 months (95% CI 9.2 – not available). Using the log-rank test, age (quartile groups), number of LOT (1-2 vs. 3-4 vs. 5+), time from cBTKi to pirto (quartile groups), Ki67≥30%, and high MIPI-C did not result in a statistically significant difference in PFS (p>0.05). Presence of TP53 mutation was associated w/ a non-statistically significant adverse trend in PFS (p=0.0585). No response to cBTKi and Ki67≥50% were associated w/ a statistically significant inferior PFS in log-rank test (p=<0.05), which persisted in a MV Cox regression model (aHR 2.4, 95% CI 1.4-4.2, and aHR 2.6, 95% CI 1.6-4.4, respectively). Conclusions: This is the first RW report on pirto in MCL pts. In this high-risk population, ORR to pirto was comparable to the BRUIN trial, while PFS was significantly worse, especially in pts w/ no response to cBTKi and w/ a high Ki67. However, prolonged remissions were seen in a subset of pts, suggesting that a better characterization of this population w/ durable benefit from pirto is needed.
Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity
Dooley, Katharine , Corraes, Andre De Menezes Silva , Carabenciov, Darin D., Hwa, Yi L. , Stephens, Haily, Kapoor, Prashant , Tan, Melinda Si Yun , Kourelis, Taxiarchis , Warsame, Rahma , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier, Julia E. , Geyer, Susan M. , Zanwar, Saurabh , Abdallah, Nadine , Kumar, Shaji, Ζεκερίδου, Αναστασία , Wiedmeier-Nutor, Julia E , Lim, Kenneth J C , Parrondo, Ricardo D , Chhabra, Saurabh , Gertz, Morie A. , Stephens, Haily, Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Ailawadhi, Sikander , Fonseca, Rafaël , Kumar, Shaji , Lin, Yi

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5953-5953

10.1182/blood-2025-5953 Get It

Abstract Introduction Cila-cel is associated with a 10-15% risk of delayed neurotoxicity (DNT) with rates of cranial nerve palsies (IEC-NP) and parkinsonism (IEC-PKS) seen at a rate of 10% and 1-4% respectively and can occur as early as 3-4 weeks after infusion. We and others have shown that high post-infusion peak absolute lymphocyte count (ALCpeak) of >3x10^9/L is associated with an increased risk of delayed neurotoxicity (Lim et al., ASCO 2025) whilst the risk was negligible (~1%) when ALCpeak fell below that threshold. Since December 2024, we implemented prophylactic administration of dexamethasone (PPX DEX) when ALC was >3x10^9/L (defined as high ALCpeak). Outcome of these patients are described here. Methods Analysis of clinical outcome included 230 pts treated between Feb 2022 and Nov 2024 as a historical cohort and 102 patients treated between Dec 2024 and May 2025 after the introduction of dexamethasone prophylaxis using an oral dose of 10mg twice a day for at least three days in the high ALCpeak cohort. Results No significant differences were seen between the new and historical cohort in pre-lymphodepletion disease burden (bone marrow plasma cell %, involved light chain or M-spike level), and rates of all/high-grade CRS or ICANS, IEC-HS and rates of tocilizumub use. Median follow-up in the new cohort of 102 pts was 3.6 months (95% CI 3.3-4.2). Eleven (10.8%) developed DNT [3 (2.9%) with IEC-PKS, 8 (7.8%) with IEC-NP]. High ALCpeak of >3x10^9/L was observed in 51 (50%) pts. Among pts with high ALCpeak, DNT was observed in 10 (20%) pts [3 (5.9%) with IEC-PKS, 7 (13.7%) with IEC-NP] whereas among 51 pts with ALCpeak <3x10^9/L, DNT was observed in 1 (2%) pt [1 (2%) with IEC-NP]. In the high ALCpeak cohort, 38 (75%) received DEX [6 (12%) for toxicity management, 32 (63%) PPX DEX]. Of the 38 pts treated with DEX, DNT was observed in 6 (16%) pts (2 (5.3%) IEC-PKS, 4 (10.5%) IEC-CNP). We next compared DNT rates between this new cohort of high ALCpeak pts receiving DEX (n=38) against the historical cohort with high ALCpeak (n=98). Estimated 90-day DNT by Kaplan-Meier method was (19.2% vs 20.5%; p=0.53): IEC-PKS (5.8% vs 7.2%; p=0.60) and IEC-NP (11.7% vs 13.3%; p=0.58). In patients with high ALCpeak, the use of DEX did not appear to significantly reduce the risk of DNT compared to historical controls (HR 0.76, 0.33-1.78), IEC-PKS (HR 0.67, 0.14-3.10) or IEC-NP (0.73, 0.24-2.23). We next compared ALC expansion over the first month post CAR-T infusion (area under the curve, AUC). Among the new cohort of 102 patients, no difference was seen in the AUC of pts who received DEX but did not develop DNT vs those who developed DNT (31.0 vs 57.9, p=0.28); No difference in AUC was seen in the new high ALCpeak cohort receiving DEX vs the historical cohort with high ALCpeak (36.0 vs 43.8, p=0.15) Of the eight cases of IEC-NP, 4 received PPX DEX. No noticeable differences were observed in the severity of presentation, laterality of cranial nerve involvement and rates of multiple cranial nerve involvement between these 4 cases who received PPX DEX and the 16 cases from the historical cohort. At the time of database freeze, 3 of the 4 cases had resolved and 1 was improving. Median time to complete symptom resolution was 38 days vs 69 days in the historical cohort. Of the three cases of IEC-PKS, 2 received PPX DEX. Median time to symptom onset for IEC-PKS was 46 days (vs. 24 days in historical cohort). Both cases had severe symptoms non-responsive to first line high-dose methylprednisolone, second line intrathecal chemotherapy and third line high-dose cyclophosphamide. Both pts subsequently died from sepsis 28 and 67 days post-cyclophosphamide. Conclusion While ALCpeak >3x10^9/L predicts risk of DNT in pts treated with cilta-cel, the use of PPX DEX does not appear to significantly reduce ALC expansion and does not appear to significantly reduce the risk of DNT, IEC-PKS or IEC-NP. Other strategies to reduce ALC or alter T cell functions may need to be considered.
Anti-PF4 antibodies are a potential mediator of antisense oligonucleotide (ASO)-induced thrombocytopenia.
Singh, Avinash Kumar , Cousin, Margot A. , Bird, Sophia , Kanack, Adam J. , Padmanabhan, Anand , Singh, Avinash , Singh, Avinash Kumar , Demeler, Borries

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 204-204

10.1182/blood-2025-204 Get It

Abstract Introduction: Antisense oligonucleotides (ASOs) technology has emerged as a transformative approach in molecular therapeutics, offering precise regulation of gene expression. ASOs are short, synthetic single-stranded nucleic acids that bind to target RNA sequences via Watson–Crick base pairing. Depending on their chemical modifications (e.g., phosphorothioate linkages) and sequence design (e.g., aptamer, gapmer), ASOs can mediate RNA degradation via RNase H, modulate pre-mRNA splicing, or inhibit translation. This targeted mechanism of action positions ASOs as promising treatments for a variety of genetic, inflammatory, and neoplastic diseases. More than 10 ASOs have received regulatory approval. However, safety concerns like injection site reactions, thrombocytopenia, renal toxicity, and liver enzyme elevations have somewhat limited their broader clinical application. Notably, Inotersen and Volanesorsen were associated with severe thrombocytopenic events, including fatalities in phase 3 trials of Volanesorsen. This clinical profile of ASO-associated thrombocytopenia mirrors some aspects of heparin-induced thrombocytopenia (HIT), an immune-mediated condition triggered by anti-platelet factor 4 (PF4) antibodies recognizing PF4–heparin complexes. Hypothesis & Methods: This study investigated the hypothesis that PF4, a positively charged protein, interacts with negatively charged ASOs to form immunogenic complexes that expose neoepitopes, triggering recognition by pathogenic antibodies from HIT patients. Twelve ASOs, Inotersen, Eplontersen, Olezarsen, Fomivirsen, Mipomersen, Tofersen, Nusinersen, Eteplirsen, Golodirsen, Viltolarsen, Casimersen (all FDA approved) and Volanesorsen (EMA approved) were evaluated in this study. All twelve ASOs had lengths ranging from 18 to 30 nucleotides. The association of HIT patient antibodies with ASO-PF4 complexes was evaluated by ELISA and analytical ultracentrifugation. Functional testing was performed with donor platelets treated with ASOs. Results: HIT antibodies recognized PF4–ASO complexes in 7 out of 12 ASOs in a stoichiometry-dependent manner, similar to PF4-heparin complexes, with maximal binding at specific molar ratios. HIT antibodies activated platelets incubated with Inotersen and Volanesorsen, analogous to HIT antibody-mediated activation of heparin-treated platelets in assays such as the serotonin release assay. Interestingly, the addition of Fomivirsen and Eteplirsen induced platelet activation independent of HIT antibodies. Many ASOs have phosphorothioate [PS] linkages, a modification that enhances stability to nuclease digestion and confers additional pharmacokinetic advantages. All ASO-PF4 complexes recognized by HIT antibodies in ELISA and those that supported HIT antibody-mediated platelet activation contained PS linkages. Removal of PS linkages from a PS-containing ASO, Inotersen, abolished antibody binding to PF4-Inotersen complexes, and HIT antibody-mediated platelet activation of Inotersen-treated platelets. Conversely, introducing PS linkages into a non-PS containing ASO, Viltolarsen conferred immunogenic properties to the modified ASO, supporting both recognition by HIT antibodies in ELISA and activation of platelets by HIT antibodies. A platelet binding assay revealed nearly five-fold greater HIT antibody binding to human platelets pretreated with PS-modified ASOs compared to their PS-free counterparts. Analytical ultracentrifugation confirmed that PF4 formed large aggregates immediately upon interaction with PS-containing ASOs. Additionally, we isolated and recombinantly expressed a human monoclonal HIT-like antibody that recognizes PF4–ASO complexes in ELISA and activates ASO-treated platelets in functional assays which could serve as a valuable reagent to investigate ASO-mediated thrombocytopenia.Conclusion: With two ASOs, Fomivirsen and Eteplirsen, direct activation of platelets was noted. Studies with additional ASOs revealed a novel immune mechanism involving ASO-PF4 complex formation and anti-PF4 antibody recognition that can plausibly mediate ASO-induced thrombocytopenia. These findings highlight the key role PS linkages may play in ASO immunogenicity and provide a mechanistic framework for risk mitigation in ASO drug design, supporting the safer development and broader application of ASO therapeutics.
A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era
Kirkwood, Amy A. , Yohannan, Binoy, Weverling, Flores , Simone, Valeria Di , Kumar, Shaji, Petropoulos, Ιoannis , Cohen, Oliver C. , Stamatelopoulos, Κimon , Mahmood, Shameem, Schwotzer, Rahel , Wechalekar, Ashutosh , Gillmore, Julian D , Khwaja, Jahanzaib , Milani, Paolo, Theodorakakou, Foteini , Kumar, Shaji , Ravichandran, Sriram , Mussinelli, Roberta , Cohen, Oliver , Muchtar, Eli , Gillmore, Julian D. , Briasoulis, Αlexandros , Gertz, Morie A. , Minnema, Monique C , Dispenzieri, Angela , Palladini, Giovanni , Kastritis, Efstathios , Wechalekar, Ashutosh D.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 577-577

10.1182/blood-2025-577 Get It

Abstract Background: Systemic AL amyloidosis is an incurable disorder caused by misfolded light chain fibrils. Survival is determined by the extent of cardiac involvement and response to therapy. Mayo 2012 (stage I-IV) and European modified Mayo 2004 (stage I-IIIB) prognostic scores were developed in a historic treatment era, prior to widespread bortezomib and daratumumab use. These no longer discriminate those with the poorest outcomes. We presented a new model sub-stratifying IIIB into a high risk, ‘IIIC’ group, incorporating longitudinal strain (LS) to the European modified score (IIIC: LS >-9% + NT-proBNP >8500ng/L + high-sensitivity troponin T [hs-TnT] >50ng/L) in the bortezomib-era (2015-2019) last year (Khwaja et al, ASH 2024). Here, we present an independent external validation of the IIIC model in the modern treatment era. Methods: The ‘IIIC model’ was derived from a large real-world cohort of adults from the UK National Amyloidosis Centre (2015-2019). Performance was externally validated across Europe (Greece, Italy, Netherlands, Switzerland), USA (2015-2024) and UK (2020-2024). Survival estimates were generated from diagnosis to death or last follow-up using the Kaplan-Meier method and groups compared using Cox regression (using Stata v18). Stage IIIB and IIIC were defined as follows IIIB: LS <-9%, NT-proBNP >8500ng/L, hs-TnT >50ng/L and IIIC: LS >-9%, NT-proBNP >8500ng/L, hs-TnT >50ng/L, respectively. Stage I, II and IIIa were defined as previously described in the European modification of Mayo 2004 staging system. Results: 2493 patients were analysed from 2015-2024 (derivation, n=573; validation: Europe, n=374, USA n=458, UK, n=1088). In the derivation cohort, LS ≥-9% and standard cardiac biomarkers (NT-proBNP 332ng/L and 8500ng/L and hs-TnT>50ng/L) were selected as independent prognostic factors in a multivariable model. In the European and UK validation cohort (n=1462), median age at diagnosis was 67 years (range 35-95) with 1014 (69%) cardiac and 869 (60%) renal involvement. Median difference in involved and uninvolved free light chain (dFLC) was 181 mg/L (range 0-24933), NT-proBNP 1911ng/L (range 42-70000), hs-TnT 45ng/L (range 3-1221) and LS -14.7% (range -3- -28). In the US cohort median NT-proBNP was 1764 (range 13-71000) and hs-TnT 44 (6-687). Applying the new model staging, the patient stages were across Europe and UK were stage I: 224 (15%), II: 627 (43%), IIIA: 396 (27%), IIIB: 139 (10%) and IIIC: 76 (5%), respectively. 592 (41%) were treated with first-line daratumumab-based regimens. In the US dataset stage I: 103 (22%), II: 176 (38%), IIIA: 131 (29%), IIIB: 48 (10%) and IIIC: 16 (3%), respectively. 234 (51%) were treated with first-line daratumumab-based regimens. At a median follow-up of 30 months (95% CI 28-32) in the European and UK validation cohort, estimated median overall survival (OS) was not reached and 2-year OS was 74% (95% CI 72-77). Median survival for stages I-II, IIIA, IIIB and IIIC were not reached (NR), 67, 31 and 10 months, respectively (p<0.001). Hazard ratios for stage II, IIIA, IIIB, IIIC were 2.01 (95% CI 1.32-3.07), 3.51 (95% CI 2.31-5.35), 5.67 (95% CI 3.60-8.91) and 11.12 (95% CI 6.93-17.87), respectively (p<0.001). This was confirmed in the US cohort with a median survival for respective stages were NR, NR, NR, 8 and 2 months (p<0.001). External validation in the European and UK cohorts exhibited good predictive performance: 12-month calibration slope was 1.00 (95% CI 0.81-1.20, p=0.98), Harrel's C was 0.90 (95% CI 0.76-1.00), Royston's D 1.07, R2D 0.21 (95% CI 0.15-0.28). In 1462 patients with dataset available, stage IIIC discriminated the poorest outcome despite a greater proportion treated with first-line daratumumab v IIIB in the validation cohort (59% v 40%, p=0.008). 12-month OS for IIIC v IIIB was 44% (95% CI 32-55) v 69% (95% CI 60-76), specificity for 12-month OS 97% v 92% and diagnostic odds ratio 6.62 v 2.36. Conclusions: This study validates the new staging system from stage I-IIIC with robust identification of an ultra-poor prognostic group (Stage IIIC) in a contemporarily treated patient cohort. Despite novel therapies, the OS remains <12 month in the IIIC group and also poor in stage IIIB with median OS 31 months compared to a median of >5 years for all other stages. This staging system can be considered as a new standard of care for risk stratification of AL amyloidosis. Novel approaches are required for patients with advanced risk.
Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy
Shreve, Jacob , Khurana, Arushi , Kapoor, Prashant , Johnston, Patrick B. , Kumar, Shaji , Ansell, Stephen, Kharfan‐Dabaja, Mohamed A. , Haddad, Tufia C. , Lin, Yi, Paludo, Jonas , Guzman, Emmanuel Contreras , Gertz, Morie A. , Wang, Yucai , Binder, Moritz , Villasboas, José C. , Bennani, N. Nora , Hilal, Talal , Iqbal, Madiha , Moustafa, Muhamad Alhaj , Parrondo, Ricardo D , Chhabra, Saurabh , Rosenthal, Allison , Lin, Yi‐Sheng

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2563-2563

10.1182/blood-2025-2563 Get It

Abstract Background Chimeric-antigen-receptor (CAR) T-cell therapy has transformed outcomes for relapsed or refractory hematologic malignancies, yet early identification of patients at highest risk for death remains elusive. A prognostic model that leverages only the information routinely available at the time of CAR-T evaluationcould guide pre-infusion counseling, intensity of follow-up, and resource allocation. Methods We analyzed a prospectively maintained cohort of CAR-T recipients treated at Mayo Clinic to develop and test our model. For each patient, data (vital signs, lab results, cardiac assessments [ECG and echocardiography], and PET/CT images) from initial CAR-T evaluation (up to 60 days prior to CAR-T infusion) was considered. Vital signs and labs were left un-imputed, while ECG, echocardiographic parameters, and PET/CT features were forward-filled from the preceding 60 days. Each patient-day was labeled as “outcome present” or “no outcome,” enabling supervised training of gradient-boosting models to predict overall survival (OS) at 6 months post CAR-T infusion. Model performance was evaluated using the area under the ROC curve (AUC) with 10,000-fold bootstrapping with data shuffling between each iteration to derive confidence intervals for stability. To enhance interpretability, we also developed a simplified model using the top 19 features (determined by Shapley value-based importance), aiming to preserve predictive accuracy with a smaller feature set. Results A total of 570 CAR-T cell treated patients were included in this study (476 patients in the training cohort and 94 patients in the validation cohort). The median age was 64 years and 61% males. The primary diagnoses were B-cell lymphoma (324 patients) and multiple myeloma (246 patients). A total of 4,851 individual vital-sign readings, 11,781 laboratory measurements were included. PET/CT images were available in 318 patients. The ML model demonstrated high discriminative ability for predicting OS at 6 months post CAR-T infusion. Vital signs alone produced a mean AUC of 0.63; radiomics features alone produced a mean AUC of 0.71, while laboratory tests alone produced a mean AUC of 0.84. The features most contributory to each single-modality model were then combined into a simplified multimodal model with a total of 19 features, which produced a mean AUC of 0.87, with a 95% CI of 0.73 - 0.97. The 19 features included in the simplified model were: LDH, ferritin, uric acid, eosinophils, fibrinogen, D-dimer, heart rate, mean arterial blood pressure, QTc, QT interval, and the radiomics features of sphericity, first-order Kurtosis, first-order mean, first-order energy, first-order total energy, shape maximum2D diameter (sagittal plane), SUV CoV, SUVp90, shape flatness. This multimodal predictive model was then applied to the validation cohort (uninvolved with model training or testing), which produced an AUC of 0.93, with a 95% CI of 0.84 - 0.98. Conclusions Our ML-driven approach successfully predicts overall survival 6 months post CAR-T infusion, highlighting those individuals at most risk of poor outcomes at the time of CAR-T evaluation. The strong performance of the multimodal version of the model suggests that each data domain contributes complementary resolving power, and by including novel data types, such as PET CT radiomics features, the most accurate predictions could be realized. By providing accurate, near-real-time risk stratification for poor outcomes within 6 months of CAR-T infusion, the model could facilitate proactive patient management. Prospective studies of the integration of this ML model into CAR-T treatment workflows will be crucial to confirm its clinical benefits and to facilitate its adoption in practice.
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study
Cohen, Jonathon B. , Shah, Nirav N. , Ujjani, Chaitra S. , Kim, Won Seog , Alencar, Alvaro J. , Lewis, David , Woyach, Jennifer A. , Maddocks, Kami J. , Seymour, John F. , Nagai, Hirokazu, Vose, Julie, Fakhri, Bita , Hoffmann, Marc , Hernandez‐Ilizaliturri, Francisco J. , Kumar, Anita , Munir, Talha, Tsai, Donald E. , Abada, Paolo, Balbas, Minna, Eyre, Toby A. , Fakhri, Bita , Wang, Michael , Jurczak, Wojciech , Zinzani, Pier Luigi , Cheah, Chan Y. , Koh, Youngil , Nasta, Sunita , Flinn, Ian W. , Tessoulin, Benoit , Ma, Shuo , Patel, Krish , Wang, Yucai , Rhodes, Joanna , Tam, Constantine S. , Hoffmann, Marc, Zelenetz, Andrew D. , Li, Jian , Wang, Ying , Roeker, Lindsey E.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 665-665

10.1182/blood-2025-665 Get It

Abstract Background: Despite the efficacy of covalent Bruton tyrosine kinase inhibitors (cBTKi) in R/R MCL, patients (pts) ultimately discontinue treatment due to intolerance or development of resistance and disease relapse. Pirtobrutinib is a highly selective, non-covalent BTKi that inhibits BTK with low nM potency throughout the daily dosing interval. Pirtobrutinib was safe and effective in the phase 1/2 BRUIN study in pts with R/R B-cell malignancies, including those previously treated with a BTKi. Pirtobrutinib is approved in the EU for adults with R/R MCL after prior treatment with a BTKi (EMA Conditional Approval, Oct 2023), and in the USA for adults with R/R MCL after ≥ 2 lines of systemic therapy, including a BTKi (FDA Accelerated Approval, Jan 2023).Here, we report the final results from the phase 1/2 BRUIN study (NCT03740529), with a follow-up period of up to 5 yrs, focusing on the efficacy and safety of pirtobrutinib in all R/R MCL pts. Methods: Pts with R/R MCL who received ≥1 prior lines of therapy (including BTKi) were eligible for treatment with pirtobrutinib monotherapy. Key endpoints included overall response rate (ORR), duration of response (DOR) and progression-free survival (PFS), all assessed by independent review committee (IRC) per Lugano 2014 criteria (presented here) and investigator, overall survival (OS), and safety. Pts were included across the range of doses evaluated in dose escalation and expansion (25-300 mg/day). A data cutoff on 27 January 2025 was utilized, with a median study follow-up of 17.5 months (range, 0.5-69.6). Results: Among the 166 pts with R/R MCL, 153 (92%) received the pirtobrutinib approved dose of 200 mg/day, 152 (92%) had received prior cBTKi, of which 128 (84.2%) discontinued any prior cBTKi due to progressive disease (PD), and 15 (9.9%) due to toxicity. The cBTKi-pre-treated pts had a median age of 70 yrs (range, 46-88), 52% had intermediate-risk and 28.3% had high-risk sMIPI scores. The median number of prior lines of therapy was 3 (range 1-9), with most pts having received a prior anti-CD20 antibody (96.7%) and chemotherapy (90.1%). Additional prior therapies included hematopoietic stem cell transplantation (21.7%; 19.7% auto and 4.6% allo), BCL-2 inhibitor (15.8%), CAR-T cell therapy (8.6%). As of the data cutoff, 11 (7.2%) pts who received a prior cBTKi and 6 (42.9%) cBTKi naïve pts remained on treatment. The cBTKi pre-treated pts had an ORR of 49.3% (95% CI, 41.1-57.6), including 15.8% complete responses (CR) (n=24) and 33.6% partial responses (PR) (n=51). The 75 responding pretreated pts had a median DOR of 21.6 months (95% CI, 9.2-27.2) at a median follow-up of 24 months. The ORR among 128 pts who had discontinued any prior cBTKi due to PD and 15 pts who discontinued due to toxicity was 43.0% and 93.3%, respectively. The median PFS and OS for cBTKi pre-treated pts were 5.6 months (95% CI, 5.3-9.2) and 23.9 months (95% CI, 17.3-51.5), respectively. Fourteen pts (9.2%) were censored for PFS due to subsequent anticancer therapy without documented PD, including 8 pts who received CAR-T. The cBTKi naïve pts (n=14) had an ORR of 85.7% (95% CI, 57.2-98.2), including 50.0% CR (n=7) and 35.7% PR (n=5). The 12 responding naïve pts had a median DOR of 42.7 months (95% CI, 25.8-NE) at a median follow-up of 43 months. The median PFS and OS in the cBTKi naïve pts were 44.6 months (95% CI, 16.7-NE) and not reached (95% CI, 33.5-NE), respectively. Among all R/R MCL pts (n=166), the most frequent treatment-emergent adverse events (TEAE), regardless of attribution, were fatigue (31.9%), diarrhea (22.9%), anemia (18.1%), and dyspnea (18.1%). The most common Grade ≥3 TEAE was neutropenia/neutrophil count decreased (13.3%), and the rate of Grade ≥3 infections was 21.1%. Grade ≥3 hemorrhage/hematoma (2.4%) and all-grade atrial fibrillation/flutter (3.6%) were infrequent. In total, 13 (7.8%) pts had a fatal TEAE, with 4 (2.4%) classified as infections. Overall, 8 pts (4.8%) had treatment-related AE leading to dose reductions, and 6 (3.6%) had treatment-related AE leading to pirtobrutinib discontinuation. Conclusion: Pirtobrutinib continues to demonstrate efficacy in pts with heavily pre-treated R/R MCL including both those who previously received a cBTKi and those who were BTKi-naïve. The safety profile of pirtobrutinib remained favorable with a low-rate of dose reductions/discontinuations due to drug-related toxicity. No new safety signals were identified after up to 5 yrs of follow-up.
Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses
Ahsan, Aarif, Mantis, Christine, Luo, Adam , Zheng, Pingping , Liu, Wei , Zhang, Catherine, Rodriguez, Cesar, Voorhees, Peter M. , Safah, Hana, McKay, John, Korde, Neha , Vij, Ravi , Kumar, Shaji, Mian, Hira , Pothacamury, Rajvineeth Kumar, Svensson, Anders , Mian, Hira , D’Souza, Anita , Chung, Alfred , Tuchman, Sascha Alexander , Weisel, Katja C , Teipel, Raphael , Kumar, Shaji , Baljević, Muhamed , Talati, Chetasi , Ross, Jeremy A.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2204-2204

10.1182/blood-2025-2204 Get It

Abstract Background Etentamig is a second-generation B-cell maturation antigen (BCMA) x CD3 bispecific antibody that has shown promising efficacy and a favorable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Etentamig possesses a unique combination of 2 high-affinity BCMA binding domains, coupled to a low-affinity CD3 binding domain that have been shown to reduce the negative impact of soluble BCMA (sBCMA), decrease risk for cytokine release syndrome (CRS), and drive sustained T-cell activation with reduced immune exhaustion in preclinical models of MM (Blood 2023;142 [suppl 1]:4666). Here, we describe correlative biomarker analyses from Phase 1 (NCT03933735) and Phase 1b (NCT05650632) clinical trials of etentamig in RRMM designed to assess the impact of sBCMA on clinical response and pharmacodynamic changes in proinflammatory cytokines, and T-cell redistribution, activation, proliferation, and exhaustion. Methods Peripheral blood and serum samples from patients with RRMM enrolled in Phase 1 and Phase 1b open-label studies who received etentamig monotherapy were collected at baseline, on treatment, and at disease progression. The Phase 1b study consisted of dose-optimization (DO) and dose-expansion (DE) phases. During DO, patients received a single step-up dose (SUD) of intravenous etentamig (2 or 4 mg) on Cycle (C) 1 Day (D) 1, followed by the target dose of 60 mg on D4. In DE, based on DO findings, patients received the recommended etentamig SUD (2 mg) on C1D1, followed by 60 mg on D4 with modified dexamethasone predosing. Samples were analyzed by flow cytometry for immune cell populations, Luminex® for cytokines, and electrochemiluminescence for sBCMA. Peripheral blood mononuclear cells and bone marrow mononuclear cells (BMMC) at baseline and on-treatment were subjected to single-cell Cellular Indexing of Transcriptomes and Epitopes sequencing (scCITEseq) and single-cell T-cell receptors (scTCR) / B-cell receptors clonality analyses. Results While baseline serum sBCMA levels did not correlate with clinical response to etentamig at the selected dose level of 60 mg every 4 weeks (Q4W) with 2 mg SUD, a reduction in sBCMA levels over time was associated with best International Myeloma Working Group response. Etentamig treatment led to a rapid and transient increase of proinflammatory cytokines and promoted T-cell redistribution, activation, and proliferation. Maximum reduction in peak levels of CRS-related cytokines, including (interleukin [IL]-6, IL-8, IL-10, tumor necrosis factor–a), were observed in DE compared with DO and 60 mg Q4W without SUD. Peak induction levels of proinflammatory cytokines during C1 correlated with occurrence of CRS (≥Grade [G] 1) as well as clinical response across dose levels. A modified dexamethasone premedication schedule of 2 mg/60 mg Q4W cohort for C1 resulted in significantly reduced baseline levels of IL-6 and key macrophage-associated cytokine/chemokines (eg, monocyte chemoattractant protein-1 and macrophage inflammatory protein-3 beta). Incidence of CRS was lowest in the 2 mg/60 mg Q4W cohort (26% G1, 4% G2, 0% ≥G3). Higher T-cell to myeloma cell ratio in BMMCs at baseline correlated with better response to etentamig. scCITEseq and scTCR analysis revealed that at baseline, responders also had greater CD8+ T-cell cytotoxic activities, increased TCR clonality, and elevated inflammatory signatures in T-cells from both peripheral blood and bone marrow. Etentamig at a dosage of 60 mg Q4W resulted in significant clonal expansion of CD8+ effector T-cells and enhanced gene expression signatures related to activation and cytotoxicity in both CD8+ T effector and natural killer cells. Along treatment cycles, responders maintained their T-cell fitness, high clonality, and low T-cell exhaustion levels. Frequency of baseline CD4+ or CD8+ T-cell exhaustion (programmed cell death receptor 1+/ T cell immunoglobulin and mucin-domain containing-3 +) did not impact clinical response at optimal dose level of 2 mg/60 mg Q4W etentamig. Conclusions Responses to etentamig were independent of baseline sBCMA levels and resulted in rapid and transient proinflammatory cytokine production that promoted robust T-cell redistribution, activation, and proliferation indicating that the optimal dose of etentamig (2 mg/60 mg Q4W) maximizes its clinical potential as a convenient, safe, and effective therapy for MM.
Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement
Xiao, Alexander , Zanwar, Saurabh , Lin, Yi , Kapoor, Prashant , Abdallah, Nadine , Fonder, Amie , Hayman, Suzanne R. , Hwa, Yi L. , Hobbs, Miriam, Kourelis, Taxiarchis , Lacy, Martha Q. , Leung, Nelson , Tan, Melinda Si Yun , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Xiao, Alexander H , Binder, Moritz , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Gertz, Morie A. , Gonsalves, Wilson I. , Muchtar, Eli , Siddiqui, Mustaqeem , Jevremović, Dragan , Rajkumar, S. Vincent

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2225-2225

10.1182/blood-2025-2225 Get It

Abstract Background Central nervous system involvement in multiple myeloma (CNS-MM) is a rare but highly aggressive manifestation. Limited data exists regarding its incidence, biology, treatment patterns, and outcomes. A deeper understanding of the features unique to CNS-MM will help inform risk stratification and management strategies. Methods We conducted a retrospective study of CNS-MM patients at our institution between January 2000 and December 2023. We identified 305 MM patients with pathology-proven extramedullary disease (EMD). CNS involvement was defined as the presence of parenchymal (brain or spine) or leptomeningeal involvement by MM. Univariate analysis was performed to compare the clinical characteristics between EMD patients with and without CNS-MM. Results Out of 305 patients with EMD, we identified 22 patients with CNS-MM. Common symptoms prompting evaluation of CNS-MM were headaches (32%), numbness or tingling (32%), weakness (27%), confusion (23%), falls (23%), and visual disturbances (14%). Among these patients, 17 (77%) had detectable disease in cerebrospinal fluid (CSF), 12 (55%) in the brain parenchyma, 4 (18%) in the spinal cord parenchyma and 6 (27%) in the leptomeninges. Of the CNS-MM patients, the median age at diagnosis of MM was 58.3 years and the median time to CNS-MM involvement was 16.2 months, with 3 (14%) patients having CNS involvement at diagnosis. The predictors of CNS-MM development were high-risk cytogenetics (OR 2.9, p=0.04) and presence of additional visceral organ involvement outside of the CNS (OR 3.4, p=0.03). EMD was multifocal in 20 CNS-MM patients (83%) and visceral organ involvement [most commonly lymphadenopathy (27%), solid organ (18%) and pleural fluid (14%)] was present in 14 (64%) of these patients, compared to 54% in EMD patients without CNS-MM. High-risk cytogenetics [del(17p), 1q gain/amplification, t(4;14), t(14;16), t(14;20)] were seen in 16 (73%) patients, most commonly 1q gain or amplification (40%), t(4;14) (23%), and del(17p) (18%). Five (23%) exhibited a double-hit profile. In comparison, 113 (40%) EMD patients without CNS-MM had high risk cytogenetics. The median overall survival (OS) from diagnosis of CNS-MM was 6 months (95%CI:1.26-36) compared to 15.6 months (95%CI: 12-18) from diagnosis of EMD in EMD patients without CNS-MM (p=0.05). Median OS from diagnosis of MM in the CNS-MM cohort was 36 months (95%CI: 22.8-NA) compared to 55.2 months (95%CI: 45.6-68.4) in EMD patients without CNS-MM (P=0.11). When excluding CAR-T or bispecific therapy recipients, median OS from diagnosis of MM for CNS-MM was 22 months versus 48 months in EMD patients without CNS-MM (P=0.02). Overall response rate in our CNS-MM cohort with first treatment for EMD was 32% compared to 48% in EMD patients without CNS-MM (p=0.04). In patients with CNS-MM, median progression-free survival (PFS) from CNS-MM diagnosis was 3.3 months (95%CI: 0.8-12) versus 3.9 months (95%CI: 3-5.1) in EMD patients without CNS involvement (p=0.2). Six (27%) CNS-MM patients received CAR-T; 3 received cilta-cel, 2 received ide-cel and one received a BCMA CAR-T on trial. Bispecific therapy was used in 4 (18%) patients, with 2 receiving Teclistamab and 2 Talquetamab. Three (14%) CNS-MM patients received both CAR-T and bispecific therapy. The median PFS on CAR-T therapy was 10.5 (95%CI: 5.6-NA) months and 12.7 (95%CI: 10.2-NA) months on bispecific therapy. The median OS from diagnosis of CNS-MM for patients who received CAR-T or bispecific therapy was 36 months (95%CI: 14.0-NA), compared to 1.2 months (95%CI: 0-14.4) for those who did not (p=0.002). Six (27%) patients with CNS-MM, all of whom had CSF involvement of disease, received intrathecal therapy; methotrexate in 3, cytarabine in 2, and one receiving both. Two of these patients demonstrated improvement in cerebrospinal fluid findings following intrathecal chemotherapy, in conjunction with other therapies. Patients who received intrathecal chemotherapy had a median OS measured from development of EMD of 10.8 (95%CI: 3.6-NA) months, compared to 15 months (95%CI: 4.8-NA) in those without IT chemotherapy (p=0.59). Conclusion Central nervous system involvement in MM is relatively uncommon and associated with dismal outcomes. High-risk cytogenetics and involvement of other visceral sites are associated with a higher risk of CNS involvement. Intrathecal therapy offers limited value and immune effector therapies represent efficacious options for treatment.
Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international con
Bláha, Ondřej , Ali, Najla Al , Stein, Eytan M. , Brunner, Andrew M. , McMahon, Christine M. , Shallis, Rory M. , Chandhok, Namrata S. , Logothetis, Constantine , Bidikian, Aram, Getz, Theodore, Harris, Amyah, Hawkins, Hayley, Ball, Somedeb , Grenet, Justin , Haferlach, Torsten , Maciejewski, Jaroslaw P. , Al-Rabi, Kamal , Halahleh, Khalid , Pleyer, Lisa , Pappa, Vassiliki, Consagra, Angela , Al‐Kali, Aref , Stahl, Maximilian , Sallman, David A. , Kewan, Tariq Zuheir , Bewersdorf, Jan Philipp , Lanino, Luca , Stempel, Jessica M. , Dezern, Amy Elizabeth , Sekeres, Mikkael A. , Uy, Geoffrey L. , Urrutia, Samuel , Carraway, Hetty E. , Desai, Pinkal , Griffiths, Elizabeth A. , Zeidner, Joshua F. , Savona, Michael R. , Roboz, Gail J. , Rolles, Benjamin , Wang, Eunice S. , Amaya, Maria L. , Xie, Zhuoer , Madanat, Yazan F. , Abaza, Yasmin , Badar, Talha , Campos, Jaclynn, Enjeti, Anoop Kumar , Hiwase, Devendra , Díez‐Campelo, María , Valcárcel, David , Haferlach, Claudia , Kotsianidis, Ιoannis , Pappa, Vasiliki , Santini, Valeria , Ogawa, Seishi , Nannya, Yasuhito , Komrokji, Rami S. , Porta, Matteo Giovanni Della , Zeidan, Amer M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3863-3863

10.1182/blood-2025-3863 Get It

Abstract Introduction TP53MT are associated with poor outcomes in MDS, especially in the context of biallelic MT. We have previously reported on outcomes of pts with HR-MDS with TP53MT who received HMA in the VALIDATE dataset (Kewan T et al, ASH 2023). Here we provide expanded analyses focusing on outcomes post allo-HCT, and we explore the prognostic significance of different classification methods for biallelic TP53MT. Methods The VALIDATE database includes 4,732 pts with MDS who received HMA-based frontline therapy from 32 international centers in 9 countries. For this study, only pts with HR-MDS with molecular data at time of diagnosis were included. Biallelic TP53MT status was assessed using three classification schemes: WHO 2022, ICC 2022, and a VAF-based Cleveland Clinic Foundation (CCF) method.1TP53 copy neutral loss of heterozygosity (CN-LOH) was evaluable in 386 pts (118 had TP53MT). Treatment responses were evaluated using IWG 2023 criteria (Zeidan A et al, Blood 2023). Composite complete remission (cCR) was defined as CR+CRbi+CRuni+CRh+CRequivalent. We calculated OS from time of HMA initiation to date of death or last follow up. Unsupervised clustering (MOSAIC framework) was applied to identify molecular subgroups within the TP53MT cohort. The study was funded by an independent grant from Abbvie. Results A total of 1,485 pts were included. Median age was 69 years (IQR: 62–76), with 66% male pts. Median bone marrow blast was 7%, and 28% had a complex karyotype. Treatment regimens included azacitidine (68%), decitabine (15%), HMA/Venetoclax (8%), and other HMA combinations (9%); 34% underwent allo-HCT. Overall, 392 (26%) had TP53MT with 430 TP53 mutations (missense: 316; truncating: 89). Biallelic TP53MT % varied by classification: 72% (WHO), 84% (ICC), and 85% (CCF). Compared to TP53 wild-type (TP53WT) pts, pts with TP53MT had worse OS (median: 11.5 vs. 23.9 months [mo], p< 0.001), were younger (68 vs. 70 years, p=0.039), and had lower counts at diagnosis. Complex karyotype (81% vs. 14%) and chromosomal abnormalities were more frequent in TP53MT pts. Pts with TP53MT also had fewer co-mutations in other genes. Response to HMA was evaluable in 1,094 pts: cCR and CR were 32% and 13%, respectively. TP53MT pts had higher cCR (39% vs. 29%, p=0.001) than TP53WT, but similar CR rates (16% vs. 12%, p=0.093). According to WHO 2022, biallelic TP53MT had higher CR rates than monoallelic TP53MT (18% vs. 8%, p=0.03), but similar cCR. ICC and CCF classifications did not differentiate response rates. Median OS did not differ by TP53MT allelic status using WHO or ICC definitions. However, using the CCF method, pts with biallelic TP53MT had shorter OS than monoallelic TP53MT (10.4 vs. 17.2 mo, p=0.038). In multivariable models adjusted for age, gender, and allo-HCT, only the CCF-defined biallelic TP53MT group had significantly worse OS (HR: 1.6; 95% CI: 1.1–2.4). TP53MT pts undergoing allo-HCT had improved OS regardless of allelic status. Median OS for TP53MT pts with allo-HCT was 18.9 vs. 9.2 mo without all-HCT. This benefit was observed across WHO, ICC, and CCF classifications. However, a TP53MT VAF ≥19% predicted worse OS even post allo-HCT (14.6 vs. 47.1 mo, p<0.001). At 1 year, the survival rate was 78% (95%CI: 69-89%) in TP53MT pts who underwent allo-HCT and had cCR vs. 68% (95%CI: 55-84%) in pts who did not have cCR. However, 1 year survival rate was significantly higher for pts with TP53MT who did not have allo-HCT and achieved cCR (60%, 95%CI: 48-76%) vs. no cCR (26%, 95%CI: 20-35%). Unsupervised clustering of 335 TP53MT pts identified 9 molecular clusters (MCs). MC2, characterized by low TP53MT VAF (median 17%), fewer co-mutations, and frequent del17p, was associated with significantly improved OS (17.9 mo) and predicted favorable outcome (HR for death: 0.6; 95% CI: 0.4–0.8). Other clusters were enriched for adverse features (e.g., high VAF, multi-hit TP53MT).Conclusions The CCF method appears to best classify biallelic TP53MT pts with worse survival in the absence of accurate assessment of LOH status. Treatment response per IWG 2023 for TP53MT pts was associated with OS only in non-transplanted pts. Allo-HCT improved survival across TP53MT subsets, but TP53 VAF ≥19% at diagnosis remained a strong negative prognostic factor. Integrative clustering revealed a less aggresive molecular subset among TP53MT pts, suggesting refined risk stratification may guide therapy in this high-risk population. Ref: 1.Bahaj et al. J Hematol Oncol 2023.
The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome
Bláha, Ondřej , Ali, Najla Al , Stein, Eytan M. , Brunner, Andrew M. , McMahon, Christine M. , Shallis, Rory M. , Chandhok, Namrata S. , Logothetis, Constantine , Bidikian, Aram, Getz, Theodore, Amaya, Maria , Hawkins, Hayley, Ball, Somedeb , Grenet, Justin , Haferlach, Torsten , Maciejewski, Jaroslaw P. , Sallman, David A. , Al-Rabi, Kamal , Halahleh, Khalid , Pleyer, Lisa , Pappa, Vassiliki, Consagra, Angela , Al‐Kali, Aref , Stahl, Maximilian , Rolles, Benjamin , Bewersdorf, Jan Philipp , Kewan, Tariq Zuheir , Stempel, Jessica M. , Lanino, Luca , Dezern, Amy Elizabeth , Sekeres, Mikkael A. , Uy, Geoffrey L. , Urrutia, Samuel , Carraway, Hetty E. , Desai, Pinkal , Griffiths, Elizabeth A. , Zeidner, Joshua F. , Savona, Michael R. , Roboz, Gail J. , Wang, Eunice S. , Xie, Zhuoer , Madanat, Yazan F. , Abaza, Yasmin , Badar, Talha , Campos, Jaclynn, Enjeti, Anoop Kumar , Hiwase, Devendra , Díez‐Campelo, María , Valcárcel, David , Haferlach, Claudia , Kotsianidis, Ιoannis , Pappa, Vasiliki , Santini, Valeria , Ogawa, Seishi , Nannya, Yasuhito , Della Porta, Matteo Giovanni , Komrokji, Rami S. , Zeidan, Amer M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3865-3865

10.1182/blood-2025-3865 Get It

Abstract Introduction: Marrow complete remission (mCR) in 2006 IWG criteria for MDS (Cheson B et al, Blood 2006) reflects achieving bone marrow (BM) blast percentage below 5% but is frequently not associated with meaningful count recovery. While mCR + hematologic improvement (HI) does reflect wide ranges of count improvement or transfusion reductions, HI is difficult to measure accurately in routine clinical practice. The 2023 International Working Group (IWG) response criteria (Zeidan A et al, Blood 2023) eliminated the mCR category without meaningful count recovery and reclassified mCR associated with meaningful count recovery into specific “less-than-CR” categories. Still, many clinical trials continue to use mCR as a secondary efficacy endpoint or as a part of overall response rate (ORR). Within the icMDS VALIDATE database, we assessed the association of mCR with OS in hypomethylating agent (HMA)-treated higher risk (HR)-MDS patients among both (1) transplanted and (2) non-transplanted patients. Methods We included patients with HR-MDS (defined as IPSS ≥1.5 and/or IPSS-R >3.5) who received HMA-based therapies from the international icMDS VALIDATE dataset. We evaluated the best response by IWG 2006 criteria into CR, mCR, or no CR/mCR. We then reclassified patients with mCR per IWG 2023 criteria into either (A) having achieved a composite CR (cCR) defined as CR + CR equivalent (CRequ) + CR with bilineage count recovery (CRbi) + CR with unilineage count recovery (CRuni) + CR with partial hematologic recovery (CRh) or (B) not having achieved cCR (no cCR). OS was calculated from time of HMA initiation to date of death or last follow-up by using 6-month landmark analyses. We used Kaplan-Meier methods to estimate OS, and the Log-rank test to compare OS. VALIDATE is supported by an independent grant from AbbVie. Results A total of1049 patients met eligibility.Median age of patients was 69 (range 21-95), 64% were men. While 61% received azacitidine, 17% received decitabine, and 22% received HMA-based combination therapy. In total, 37% underwent subsequent allogenic stem cell transplantation (allo-HCT). Based on IWG 2006 criteria, 17%, 33%, and 50% achieved CR, mCR, and no CR/mCR as their best response, respectively. Patients achieving CR had superior median OS (25 months, 95% CI: 21-34 months) compared to those with mCR (16 months, 95% CI: 13-18 months; p=0.038) and no CR/mCR (15 months, 95% CI: 12-17 months; p=0.001). In patients who received a subsequent allo-HCT, the median OS for patients with mCR (30 months, 95% CI: 21-54 months; 1 year OS: 71%, 2 year OS: 55%) did not significantly differ compared to patients with CR (59 months, 95% CI: 25 months-not reached, p=0.80; 1 year OS: 73%, 2 year OS 62%) and patients with no CR/mCR (32 months, 95% CI: 21-45 months, p=0.46; 1 year OS: 69%, 2 year OS 54%). In contrast, in patients treated with HMA therapy alone without subsequent allo-HCT, median OS for patients with mCR (11 months, 95% CI: 9-15 months; 1 year OS: 46%, 2 year OS: 23%) did not significantly differ compared to patients with no CR/mCR (11 months, 95% CI: 9-14 months, p=0.85; 1 year OS: 47%, 2 year OS: 22%) but was significantly shorter compared to patients with CR (20 months, 95% CI: 17-28 months, p<0.001; 1 year OS: 69%, 2 year OS: 46%). Patients with mCR by IWG 2006 (N=347) were reclassified per IWG 2023 into having either achieved a cCR (N=219, 63%) or no cCR (N=128, 37%). Specifically, patients with mCR were reclassified per IWG 2023 into CR (4.9%), CRequ (0.6%), CRbi (26.8%), CRuni (29.4%), CRh (1.4%), PR (0%), HI (10%), no response (21.9%) and PD (4.9%). Patients with mCR who were reclassified into cCR had an improved median OS (16 months, 95% CI: 15-26 months; 1 year OS: 62%; 2 year OS: 43%) compared to patients reclassified into no cCR per IWG 2023 (13 months, 95% CI: 11-17 months, p=0.023; 1 year OS: 52%; 2 year OS: 31%). Conclusions Using the large icMDS VALIDATE dataset, we found that achievement of mCR by 2006 IWG criteria was not associated with improved OS compared to patients who did not achieve CR/mCR. Reclassification of mCR using IWG 2023 highlights the heterogeneity within the mCR group and suggests that IWG 2023 criteria stratifies outcomes in patients previously labeled as mCR by IWG 2006. IWG 2023 should be the standard used for ORR assessment in all future clinical trials involving patients with HR-MDS.